Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free HLUYY Stock Alerts
OTCMKTS:HLUYY

H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

H. Lundbeck A/S logo
$22.00 -0.01 (-0.02%)
As of 08/9/2022
Compare

About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)

Key Stats

Today's Range
$22.00
▼
$24.00
50-Day Range
$22.00
▼
$22.00
52-Week Range
$10.00
▼
$31.55
Volume
7,500 shs
Average Volume
1,758 shs
Market Capitalization
$21.91 billion
P/E Ratio
25.00
Dividend Yield
0.91%
Price Target
N/A
Consensus Rating
N/A

Company Overview

H. Lundbeck A/S is a Denmark-based pharmaceutical company focused on developing, manufacturing and commercializing medicines for brain diseases. Its research and commercial activities address conditions including depression, schizophrenia, migraine, alcohol dependence and other neurological and psychiatric disorders.

The company’s portfolio includes Vyepti (eptinezumab) for the preventive treatment of migraine, Trintellix (vortioxetine) for major depressive disorder, Rexulti (brexpiprazole) for selected psychiatric indications, and Abilify Maintena (aripiprazole) for the treatment of schizophrenia and maintenance treatment of bipolar I disorder. Lundbeck also markets other products and medicines through its own development programs and strategic collaborations.

Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and serves patients and healthcare professionals through commercial operations in numerous countries across North America, Europe and other international markets. The company’s global activities include research, clinical development, regulatory support, manufacturing and sales. H. Lundbeck A/S is led by Chief Executive Officer Charl van Zyl.

AI Generated. May Contain Errors.

Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HLUYY Stock News Headlines

H LUNDBECK A/S A
August 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-aktien/h-lundbeck-a-s-a.htm
H LUNDBECK A/S B
July 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-aktien/h-lundbeck-a-s-b.htm
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel
September 12 at 1:00 AM  |  Paradigm Press (Ad)
H. Lundbeck A/SEO-Medium-Term Nts 2025(25/29) Bond
July 7, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/bonds/h_lundbeck_a-seo-medium-term_nts_202525-29-bond-2029-xs3081808837
Avadel board declares Lundbeck proposal superior to Alkermes offer
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/avadel-board-declares-lundbeck-proposal-superior-to-alkermes-offer/ar-AA1QBgBn
Avadel Pharmaceuticals plc Confirms Receipt of Unsolicited Acquisition Proposal from H. Lundbeck A/S
November 14, 2025  |  quiverquant.comQ
Lundbeck and Contera partner for oligonucleotide-based medicines
October 22, 2025  |  msn.comhttps://www.msn.com/en-us/news/other/lundbeck-and-contera-partner-for-oligonucleotide-based-medicines/ar-AA1OU2PX
H. Lundbeck A/S Cl B
October 12, 2025  |  barrons.comhttps://www.barrons.com/market-data/stocks/lunb?countrycode=at
See More Headlines

HLUYY Stock Analysis - Frequently Asked Questions

H. Lundbeck A/S's stock was trading at $22.00 on January 1st, 2026. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00.

H. Lundbeck A/S (OTCMKTS:HLUYY) announced its earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The company earned $547.05 million during the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%.

The following companies are subsidiaries of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/04/2015
Today
9/12/2026
Fiscal Year End
12/31/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:HLUYY
CIK
N/A
Web
www.lundbeck.com
Phone
(453) 630-1311
Fax
45-3630-1940
Employees
5,348
Year Founded
1915

Profitability

EPS (Trailing Twelve Months)
$0.88
Trailing P/E Ratio
25.00
Forward P/E Ratio
10.48
P/E Growth
N/A
Net Income
$209.69 million
Net Margins
6.74%
Pretax Margin
7.83%
Return on Equity
13.74%
Return on Assets
7.16%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
1.15
Quick Ratio
0.71

Sales & Book Value

Annual Sales
$2.59 billion
Price / Sales
8.45
Cash Flow
$3.36 per share
Price / Cash Flow
6.54
Book Value
$14.60 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
995,741,000
Free Float
N/A
Market Cap
$21.91 billion
Optionable
Not Optionable
Beta
0.68

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (OTCMKTS:HLUYY) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
17 Nobel Prize winners… one startling warning
On July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...
Porter & Company | Sponsoredtc pixel
I called NVDA at $6 - Here's what’s next…
Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...
Monument Traders Alliance | Sponsoredtc pixel